Esbriet 267 mg is a cutting-edge oral medication developed specifically for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a progressive lung disease that results in scarring (fibrosis) of the lung tissue, making breathing increasingly difficult. Manufactured by Roche, Esbriet has been clinically proven to slow the decline in lung function and improve the quality of life for patients diagnosed with this debilitating condition.
Key Product Details:
- Active Ingredient: Pirfenidone 267 mg
- Formulation: Film-coated tablet
- Administration: Oral use
- Packaging: Box containing 90 tablets
- Manufacturer: Roche Pharmaceuticals
Key Benefits of Esbriet 267 mg:
- Slows Lung Function Decline: Clinical studies confirm that Esbriet reduces disease progression by slowing the decline in forced vital capacity (FVC), a critical lung function parameter in IPF patients.
- Anti-Inflammatory and Anti-Fibrotic Effects: Pirfenidone possesses dual-action properties – reducing lung inflammation while inhibiting fibrosis, helping to prevent further lung scarring.
- Improved Exercise Capacity: Patients taking Esbriet have reported improved exercise tolerance and less breathlessness, allowing them to engage more freely in daily activities.
- Reduced Exacerbations: Studies suggest that Esbriet reduces the risk of acute IPF exacerbations, which are often life-threatening.
- Disease Modification: Unlike traditional therapies that merely alleviate symptoms, Esbriet directly modifies the progression of idiopathic pulmonary fibrosis, offering patients hope for a slower disease course.
What Is Esbriet Used For?
Esbriet is specifically indicated for patients diagnosed with:
- Idiopathic Pulmonary Fibrosis (IPF): A rare, chronic lung disease characterized by unexplained scarring of lung tissue, leading to breathing difficulties and reduced oxygen supply to vital organs.
How Does Esbriet Work?
Esbriet (Pirfenidone) works by targeting the underlying biological processes responsible for lung fibrosis. It inhibits the production of transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α), both of which contribute to inflammation and scar formation in the lungs. By modulating these pathways, Esbriet helps preserve lung function and slow disease progression.
Dosage and Administration:
- Initial Dose: Start with 267 mg (1 tablet) three times daily for the first week.
- Titration: Increase to 2 tablets (534 mg) three times daily in the second week.
- Maintenance Dose: From week three onwards, the standard dose is 3 tablets (801 mg) three times daily.
- Tablets should be taken with food to reduce the likelihood of nausea or dizziness.
Safety Information:
- Photosensitivity: Esbriet can increase sensitivity to sunlight; patients should use high-SPF sunscreen and avoid prolonged sun exposure.
- Liver Function Monitoring: Routine liver function tests are required during treatment.
- Common Side Effects: Nausea, rash, fatigue, dizziness, diarrhea, and loss of appetite.
- Drug Interactions: Avoid grapefruit juice and certain antibiotics (e.g., ciprofloxacin) as they may alter Esbriet’s effectiveness.
Why Choose Esbriet 267 mg?
Esbriet 267 mg is among the most widely prescribed and clinically validated treatments for Idiopathic Pulmonary Fibrosis. With its unique anti-fibrotic and anti-inflammatory mechanisms, Esbriet offers patients a scientifically proven way to slow disease progression, extend lung function longevity, and maintain a higher quality of life. Backed by Roche’s commitment to innovation and patient care, Esbriet represents a lifeline for individuals battling the challenges of IPF.
Storage Conditions:
- Store at room temperature (15°C to 30°C).
- Keep away from moisture and direct sunlight.
Buy Esbriet 267 mg Online:
Looking for a reliable source to purchase Esbriet 267 mg tablets online? We offer 100% authentic products sourced directly from Roche Pharmaceuticals. Take control of your lung health and order Esbriet today – a proven solution trusted by pulmonologists worldwide for treating Idiopathic Pulmonary Fibrosis.
Değerlendirmeler
Henüz değerlendirme yapılmadı.